Tumor Genomic Profiling in Breast Cancer Patients Using Targeted Massively Parallel Sequencing
Technical Report,01 Jan 2013,31 Dec 2015
Dana-Farber Boston United States
Pagination or Media Count:
The overarching goal of this proposal is to use massively parallel sequencing to detect somatic genomic alterations in breast cancer tumor samples in order to identify genetic determinants of tumor behavior that may inform clinical decision-making. We have developed a targeted sequencing platform that interrogates 450 genes that are known to be altered in breast cancer and other cancers. We ultimately plan to utilize this platform to study 150 tumor samples from women with ER breast cancer who have had early-, late- or no relapse following endocrine therapy. We have also sequenced tumor samples from patients with advanced breast cancer. To date, we have obtained metastatic tumor biopsies and successfully performed whole exome sequencing from more than 240 patients with metastatic breast cancer, as well as matched pre-treatment primary tissues in more than 130 of these patients. In 80 of these patients, clinically relevant genomic and molecular has been returned to the clinical team to aid with decision making in many cases, this information has impacted both treatment decisions as well as ultimate outcomes.
- Genetic Engineering and Molecular Biology
- Medicine and Medical Research